Essex Bio-Technology Limited (HKG:1061)

Market Cap	2.51B +57.6%
Revenue (ttm)	1.72B +3.1%
Net Income	313.18M +19.1%
EPS	0.55 +22.5%
Shares Out	567.01M
PE Ratio	8.04
Forward PE	7.77
Dividend	0.14 (3.17%)
Ex-Dividend Date	Sep 8, 2025

Volume	240,000
Average Volume	425,800
Open	4.370
Previous Close	4.420
Day's Range	4.340 - 4.500
52-Week Range	2.600 - 6.120
Beta	-0.12
RSI	57.78
Earnings Date	Mar 20, 2026

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 1,426
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1061

Financial Performance

In 2024, Essex Bio-Technology's revenue was 1.67 billion, a decrease of -3.87% compared to the previous year's 1.74 billion. Earnings were 307.22 million, an increase of 11.61%.